Newton, Massachusetts, (Nov. 05, 2019)
AcuityBio Corporation, a developer of novel drug-delivery combination products, announced that it has received a notice of allowance from the United States Patent and Trademark Office for Application 20170172720 . “
“We are extremely pleased to have received this patent allowance. This allowance further validates the novelty of our approach and supports our position as leader in the field of surgically-targeted polymer drug delivery. We look forward to the allowance of additional patents pending in US and worldwide this coming year. Allowance of these patents will further help us secure our proprietary position within the drug delivery space.” said AcuityBio President and CEO John “Jay” Schwartz, PhD.
AcuityBio Corporation is focused on the commercialization of novel polymer drug-delivery technologies to treat various types of early stage, soft tissue cancers. The company’s lead product candidate “ABC103” utilizes the FDA-approved drug paclitaxel with 510(k)- cleared components, creating a proprietary solution to prevent post-surgical lung cancer recurrence.. ABC103 is designed to be administered at the time of surgery with approved endoscopic cutting staplers as part of standard surgical procedures enabling localized and sustained levels of paclitaxel for 60 – 100 days to at-risk sites, thereby preventing recurrence. ABC103 program is slated to enter clinical Phase I/II testing Q4, 2020. ABC103 can be safely co-administered as an adjuvant to immune-oncology drugs to enhance their efficacy. AcuityBio’s ABC drug-delivery platform can be configured in different form factors to deliver paclitaxel as well as easily engineered to deliver many other drugs other than paclitaxel. For more information visit www.acuitybio.com.
AcuityBio’s Forward-Looking Statement Disclaimer
Various statements in this release concerning AcuityBio’s future expectations, plans and prospects, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors. In addition, any forward-looking statements represent AcuityBio’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. AcuityBio does not assume any obligation to update any forward-looking statements unless required by law. AcuityBio Contact: John “Jay” Schwartz, PhD CEO and President email@example.com